Madrigal Pharmaceuticals, Inc. MDGL
Deals with insiders in the proxy filed Apr 28, 2026
Proxy, Item 404Deals between MDGL and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 29, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 29, 2025.
Certain Relationships and Related Party Transactions“the amounts involved exceeded or will exceed $120,000; and • any of our directors, executive officers or holders of more than five percent of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.”
Read it in the proxyopen_in_new
Waiver Under 2017 Securities Purchase Agreement“Julian C. Baker and Raymond Cheong, M.D., Ph. D., who are members of our Board, are affiliated with BBA. Mr. Baker is a managing member of BBA and Dr. Cheong is a Managing Director of BBA. BBA is a beneficial owner of more than five percent of our capital stock. In connection with the appointment of Mr. Baker and Dr. Cheong to the Board, BBA waived rights under that certain Securities Purchase Agreement, dated June 20, 2017, by and among certain funds affiliated with BBA (the “BBA Investors”) and the other investors party thereto, as amended by Amendments No. 1 and 2 (collectively, the “SPA”), to designate a director to the Board while Mr. Baker or Dr. Cheong are on the Board or to appoint a Board observer under the SPA while Mr. Baker or Dr. Cheong are on the Board or serving as a Board observer.”
Read it in the proxyopen_in_new
New wording of the review policy 1 paragraph without an amount or a name
Certain Relationships and Related Party Transactions“Other than compensation arrangements for our NEOs and directors, and except as disclosed below, there have been no transaction or series of similar transactions, since January 1, 2025, or any currently proposed transactions, to which we were a party or will be a party, in which:”
Read it in the proxyopen_in_new
The whole section
As filed
9 paragraphs quoted as filed
Certain Relationships and Related Party Transactions“Other than compensation arrangements for our NEOs and directors, and except as disclosed below, there have been no transaction or series of similar transactions, since January 1, 2025, or any currently proposed transactions, to which we were a party or will be a party, in which:”
Read it in the proxyopen_in_new
Certain Relationships and Related Party Transactions“the amounts involved exceeded or will exceed $120,000; and • any of our directors, executive officers or holders of more than five percent of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.”
Read it in the proxyopen_in_new
Waiver Under 2017 Securities Purchase Agreement“Julian C. Baker and Raymond Cheong, M.D., Ph. D., who are members of our Board, are affiliated with BBA. Mr. Baker is a managing member of BBA and Dr. Cheong is a Managing Director of BBA. BBA is a beneficial owner of more than five percent of our capital stock. In connection with the appointment of Mr. Baker and Dr. Cheong to the Board, BBA waived rights under that certain Securities Purchase Agreement, dated June 20, 2017, by and among certain funds affiliated with BBA (the “BBA Investors”) and the other investors party thereto, as amended by Amendments No. 1 and 2 (collectively, the “SPA”), to designate a director to the Board while Mr. Baker or Dr. Cheong are on the Board or to appoint a Board observer under the SPA while Mr. Baker or Dr. Cheong are on the Board or serving as a Board observer.”
Read it in the proxyopen_in_new
Policy for Approval of Related Person Transactions“Pursuant to the written charter of our Audit Committee, the Audit Committee is responsible for reviewing and approving, prior to our entry into any such transaction, all transactions in which we are a participant and in which any of the following persons has or will have a direct or indirect material interest:”
Read it in the proxyopen_in_new
Policy for Approval of Related Person Transactions“the immediate family members of any of the foregoing persons; and • any other persons whom the Board determines may be considered related persons.”
Read it in the proxyopen_in_new
Policy for Approval of Related Person Transactions“For purposes of these procedures, “immediate family members” means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, and any person (other than a tenant or employee) sharing a household with any executive officer, director or five percent beneficial owner.”
Read it in the proxyopen_in_new
Policy for Approval of Related Person Transactions“In reviewing and approving such transactions, the Audit Committee obtains, or directs our management to obtain on the Audit Committee’s behalf, all information that the Audit Committee believes to be relevant and important to a review of the transaction prior to its approval. Following receipt of the necessary information, the Audit Committee holds a discussion of the relevant factors if deemed to be necessary by the Audit Committee prior to approval. If the Audit Committee does not deem a discussion to be necessary, approval of the related person transaction may be given by written consent of the Audit Committee. The Audit Committee’s related person transaction approval authority may also be delegated to the chair of the Audit Committee. No related person transaction may be entered into prior to the completion of the review by the Audit Committee.”
Read it in the proxyopen_in_new
Policy for Approval of Related Person Transactions“The Audit Committee or the chair of the Audit Committee, as the case may be, are permitted to approve only those related person transactions that are determined to be in, or not inconsistent with, our best interests and those of our stockholders, taking into account all available facts and circumstances as the Audit Committee or the chair of the Audit Committee determines in good faith to be necessary. The facts and circumstances considered in making a decision will typically include, but are not be limited to, the benefits of the transaction to us; the impact on a director’s independence in the event that the related person is a director, an immediate family member of a director or an entity in which a director is a partner, stockholder or executive officer; the availability of other sources for comparable products or services; the terms of the transaction; and the terms of comparable transactions that would be available to unrelated third parties or to employees generally. A member of the Audit Committee is not permitted to participate in any review, consideration or approval of any related person transaction with respect to which the member or any of such member’s immediate family members is the related person.”
Read it in the proxyopen_in_new
Policy for Approval of Related Person Transactions“A current copy of the Audit Committee charter is publicly available through the “Investors & Media - Corporate Governance” section of our website at www.madrigalpharma.com.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDGL/export.csv") into a cell.